The Letrozole Administration During Luteal Phase

Launched by THE AFFILIATED HOSPITAL OF INNER MONGOLIA MEDICAL UNIVERSITY · Feb 15, 2016

Keywords

ClinConnect Summary

This clinical trial, titled "The Letrozole Administration During Luteal Phase," is studying how a medication called letrozole can help women who are at high risk for a condition known as ovarian hyperstimulation syndrome (OHSS) after egg retrieval. OHSS can happen when the ovaries react too strongly to fertility treatments, leading to uncomfortable or serious symptoms. The study will compare the number of women who develop OHSS after taking letrozole to those receiving standard supportive treatment.

To participate in this trial, women must be between the ages of 18 and 40 and have certain conditions, such as having at least 20 eggs retrieved and specific hormone levels in their blood. Participants will receive either letrozole or the standard treatment and will be monitored for any signs of OHSS. It's important to note that women who are allergic to letrozole or another medication used in the study will not be eligible. This trial is currently not recruiting participants, but it aims to provide valuable information on how to better manage the risk of OHSS in women undergoing fertility treatments.

Gender

FEMALE

Eligibility criteria

• Inclusion criteria:
• • 1. oocyte is more than or equal to 20;
• • 2. hCG injection on serum estradiol levels greater than or equal to 5000 pmol/L; 3. on the day of oocyte unilateral or bilateral ovarian diameter greater than or equal to 10 cm;
• • 4. follicle puncture is larger than or equal to number 20.
• Exclusion criteria:
• • Allergic to the letrozole or polygeline.